Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

A novel approach to automating cell therapy manufacturing using industry-standard equipment can potentially reduce human errors, deliver higher quality product, and lower manufacturing costs by ...

After half a decade spent developing an automated manufacturing platform, Ori Biotech believes it's ready to make a mark on the cell and gene therapy field. Ori on Wednesday revealed its IRO platform, ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

Single-use systems streamline CGT manufacturing by reducing cleaning validation and enabling quick changeovers, essential for ...

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Sviat Dulianinov The AI ...

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs ...

Smart manufacturing is evolving beyond traditional automation toward autonomous "lights-out" factories where digital twins ...

Low-cost automation offers accessible solutions for manufacturers seeking to improve production without substantial capital investment. Simple automation tools like gravity-fed systems, basic sensors, ...